TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) was the target of unusually large options trading activity on Wednesday. Stock investors bought 9,165 call options on the company. This is an increase of approximately 230% compared to the typical daily volume of 2,781 call options.

Analysts Set New Price Targets

Several research firms have issued reports on TGTX. Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of TG Therapeutics in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Danske Bank A S purchased a new stake in TG Therapeutics during the third quarter worth approximately $25,000. Optiver Holding B.V. raised its stake in shares of TG Therapeutics by 3,485.7% in the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 732 shares during the period. Bessemer Group Inc. raised its stake in shares of TG Therapeutics by 117.1% in the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 486 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 365 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its position in TG Therapeutics by 82.7% during the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Trading Up 8.1%

TG Therapeutics stock traded up $3.53 during midday trading on Wednesday, reaching $46.90. The stock had a trading volume of 3,546,382 shares, compared to its average volume of 2,073,928. The stock’s 50-day simple moving average is $37.46 and its 200 day simple moving average is $32.77. TG Therapeutics has a twelve month low of $25.28 and a twelve month high of $49.31. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81. The stock has a market capitalization of $7.18 billion, a PE ratio of 16.43 and a beta of 1.68.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The firm had revenue of $204.92 million during the quarter, compared to analysts’ expectations of $200.33 million. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The business’s revenue for the quarter was up 69.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.03 earnings per share. Analysts expect that TG Therapeutics will post 1.51 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.